Study summary
A B7-H3 antibody-drug conjugate cut the risk of growth by 67% in relapsed osteosarcoma
67%lower risk of growth or death than gemcitabine-docetaxel
What was tested
Risvutatug rezetecan, an antibody-drug conjugate that delivers chemotherapy to cells carrying B7-H3, against gemcitabine plus docetaxel for osteosarcoma that came back or stopped responding.
What they found
- Risk of growth or death was 67% lower (hazard ratio 0.33).
- Survival data are not mature yet.
- Serious side effects, mainly low blood counts, were more common (63.8% vs 28.6%).
What it means
The first phase 3 win in relapsed osteosarcoma in decades. Not yet approved; full publication and survival data are pending.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.